One of the pioneers in biotechnology, Biogen today has the leading portfolio of medicines to treat multiple sclerosis (MS) and is at the forefront of research into new medicines for neurological conditions and rare genetic disorders. Led by world-class research and development, Biogen uses novel science and leading-edge technologies to create, commercialize, and manufacture transformative therapies for patients with few or no treatment options. Our global organization of more than 7,000 employees has a clear focus: to have the greatest impact on patients of any biotechnology company in the history of our industry.
For more than two decades, Biogen has transformed the understanding and treatment of MS. Today, our research is focused on developing new MS treatments with the goal of repairing damage caused by the disease – and ultimately working to find a cure.
We are further applying our expertise to solve some of most challenging and complex diseases in neurology, including Alzheimer’s disease, spinal muscular atrophy (SMA), Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The pace of discovery and innovation in neuroscience is accelerating rapidly, bringing the promise of incredible advances to patients. As we help lead this transformative period in neuroscience, Biogen is driving a deeper understanding of disease biology and working to develop potentially life-changing treatments for the people suffering from these conditions.
As we uncover new insights into human biology, Biogen is using cutting-edge technologies to pursue treatments for rare and genetic disorders and explore entirely new ways to treat disease through the advancement of RNA medicines and gene therapy.
Areas of Focus
Guided by science and driven to improve patients’ lives, our research and development efforts are concentrated on three core areas: multiple sclerosis (MS), neurodegeneration and rare genetic diseases.
In 2016, Biogen announced plans to spin off its leading portfolio of hemophilia assets into an independent publicly traded company dedicated to finding new treatments and potential cures for the disease. This new company, called Bioverativ, is expected to begin operating independently in early 2017.
Drawing from our deep expertise in protein engineering, Biogen is also committed to the development of biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We believe we are ideally suited to serve the growing need for high-quality, low-cost biologics through our leading global manufacturing and commercial capabilities.
The same intellectual discipline and passion that drives our science is reflected in our corporate citizenship, environmental sustainability, and commitment to diversity and inclusion. As a company, we are focused on improving science education, providing humanitarian relief, maintaining carbon neutrality, and creating a company where all employees can pursue their passion while making a difference in the lives of the patients we serve.